Astellas Sued Over Efforts To Block Generic Prograf

Law360, New York (March 1, 2011, 11:44 PM EST) -- The owners of a retail drug chain filed an antitrust class action Tuesday accusing Astellas Pharma US Inc. of abusing the U.S. Food and Drug Administration’s drug approval process to delay a generic version of Prograf and corner the market for the immunosuppressant.

Stephen L. LaFrance Holdings Inc. filed a complaint in the U.S. District Court for the District of Massachusetts claiming Astellas violated the Sherman Act by illegally maintaining a monopoly in the market for Prograf and charging supracompetitive prices for the drug.

The Pine...
To view the full article, register now.




Case Information

Case Title

Stephen L. LaFrance Holdings, Inc. et al v. Astellas Pharma US, Inc.

Case Number




Nature of Suit



Rya W. Zobel

Date Filed

February 28, 2011

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.